Cargando…

JAM-A as a prognostic factor and new therapeutic target in multiple myeloma

Cell adhesion in the multiple myeloma (MM) microenvironment has been recognized as a major mechanism of MM cell survival and the development of drug resistance. Here we addressed the hypothesis that the protein junctional adhesion molecule-A (JAM-A) may represent a novel target and a clinical biomar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Solimando, A G, Brandl, A, Mattenheimer, K, Graf, C, Ritz, M, Ruckdeschel, A, Stühmer, T, Mokhtari, Z, Rudelius, M, Dotterweich, J, Bittrich, M, Desantis, V, Ebert, R, Trerotoli, P, Frassanito, M A, Rosenwald, A, Vacca, A, Einsele, H, Jakob, F, Beilhack, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843918/ https://www.ncbi.nlm.nih.gov/pubmed/29064484 http://dx.doi.org/10.1038/leu.2017.287

Ejemplares similares

Non-Invasive Imaging Provides Spatiotemporal Information on Disease Progression and Response to Therapy in a Murine Model of Multiple Myeloma
por: Riedel, Simone S., et al.
Publicado: (2012)

Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression
por: Solimando, Antonio G., et al.
Publicado: (2020)

Non-Invasive Bioluminescence Imaging to Monitor the Immunological Control of a Plasmablastic Lymphoma-Like B Cell Neoplasia after Hematopoietic Cell Transplantation
por: Chopra, Martin, et al.
Publicado: (2013)

Junctional adhesion molecule C expression specifies a CD138(low/neg) multiple myeloma cell population in mice and humans
por: Brandl, Andreas, et al.
Publicado: (2022)

Autophagy: A New Mechanism of Prosurvival and Drug Resistance in Multiple Myeloma
por: Desantis, V., et al.
Publicado: (2018)

Microenvironment drug resistance in multiple myeloma: emerging new players
por: Di Marzo, Lucia, et al.
Publicado: (2016)

The KISS1 Receptor as an In Vivo Microenvironment Imaging Biomarker of Multiple Myeloma Bone Disease
por: Dotterweich, Julia, et al.
Publicado: (2016)

High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment
por: Solimando, Antonio Giovanni, et al.
Publicado: (2019)

The Urgent Need for Precision Medicine in Cancer and Its Microenvironment: The Paradigmatic Case of Multiple Myeloma
por: Solimando, Antonio Giovanni, et al.
Publicado: (2022)

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
por: Saltarella, Ilaria, et al.
Publicado: (2020)

Prognostic value of extracellular matrix gene mutations and expression in multiple myeloma
por: Evers, Marietheres, et al.
Publicado: (2023)

MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance
por: Desantis, Vanessa, et al.
Publicado: (2020)

Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment
por: Rudelius, Martina, et al.
Publicado: (2018)

Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules
por: Leich, E, et al.
Publicado: (2013)

Dynamic Immune Cell Recruitment After Murine Pulmonary Aspergillus fumigatus Infection under Different Immunosuppressive Regimens
por: Kalleda, Natarajaswamy, et al.
Publicado: (2016)

MicroRNAs as a Potential New Preventive Approach in the Transition from Asymptomatic to Symptomatic Multiple Myeloma Disease
por: Desantis, Vanessa, et al.
Publicado: (2021)

Novel molecular subgroups within the context of receptor tyrosine kinase and adhesion signalling in multiple myeloma
por: Leich, Ellen, et al.
Publicado: (2021)

Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma
por: Lamanuzzi, Aurelia, et al.
Publicado: (2018)

Role of Extracellular Vesicle-Based Cell-to-Cell Communication in Multiple Myeloma Progression
por: Saltarella, Ilaria, et al.
Publicado: (2021)

RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS
por: Seibold, Marcel, et al.
Publicado: (2019)

Tumor Necrosis Factor Induces Tumor Promoting and Anti-Tumoral Effects on Pancreatic Cancer via TNFR1
por: Chopra, Martin, et al.
Publicado: (2013)

PB1980: MULTIPLE MYELOMA: ADOPTING MRD BY NEXT GENERATION FLOW CYTOMETRY (NGF) AND FUNCTIONAL IMAGING GUIDED CONSOLIDATION INTO CLINICAL ROUTINE
por: Boeckle, D., et al.
Publicado: (2022)

Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin(®) protein MP0250: a preclinical study
por: Rao, Luigia, et al.
Publicado: (2018)

The Landscape of lncRNAs in Multiple Myeloma: Implications in the “Hallmarks of Cancer”, Clinical Perspectives and Therapeutic Opportunities
por: Saltarella, Ilaria, et al.
Publicado: (2022)

Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting
por: Solimando, Antonio G., et al.
Publicado: (2023)

Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma
por: Keppler, Sarah, et al.
Publicado: (2016)

Jamming transitions in cancer
por: Oswald, Linda, et al.
Publicado: (2017)

Pathways of Angiogenic and Inflammatory Cytokines in Multiple Myeloma: Role in Plasma Cell Clonal Expansion and Drug Resistance
por: Melaccio, Assunta, et al.
Publicado: (2022)

The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value
por: Desantis, Vanessa, et al.
Publicado: (2022)

Mesenchymal stem cell contact promotes CCN1 splicing and transcription in myeloma cells
por: Dotterweich, Julia, et al.
Publicado: (2014)

Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression
por: Dahlhoff, Julia, et al.
Publicado: (2021)

Uptake-Dependent and -Independent Effects of Fibroblasts-Derived Extracellular Vesicles on Bone Marrow Endothelial Cells from Patients with Multiple Myeloma: Therapeutic and Clinical Implications
por: Lamanuzzi, Aurelia, et al.
Publicado: (2023)

Exploration of Artificial Intelligence Use with ARIES in Multiple Myeloma Research
por: Loda, Sophia, et al.
Publicado: (2019)

Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma
por: Leipold, Alexander M., et al.
Publicado: (2023)

Junctional Adhesion Molecules (JAMs): The JAM-Integrin Connection
por: Kummer, Daniel, et al.
Publicado: (2018)

Anti-Angiogenic Activity of Drugs in Multiple Myeloma
por: Saltarella, Ilaria, et al.
Publicado: (2023)

A Comprehensive Biological and Clinical Perspective Can Drive a Patient-Tailored Approach to Multiple Myeloma: Bridging the Gaps between the Plasma Cell and the Neoplastic Niche
por: Solimando, Antonio Giovanni, et al.
Publicado: (2020)

Fracture of Jammed Colloidal Suspensions
por: Smith, M.I.
Publicado: (2015)

Loss of Serum and Glucocorticoid-Regulated Kinase 3 (SGK3) Does Not Affect Proliferation and Survival of Multiple Myeloma Cell Lines
por: Hausmann, Stefan, et al.
Publicado: (2015)

STAT1 overexpression triggers aplastic anemia: a pilot study unravelling novel pathogenetic insights in bone marrow failure
por: Solimando, Antonio Giovanni, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tm0nddrdig35ipo0gi0s5v7hie